They also reveal what is genuinely solid: GHRP-2 is a potent, mechanistically elegant, historically pivotal ghrelin mimetic and GH secretagogue, well established as a short-term endocrine and diagnostic tool, and unproven as a long-term therapy
Understand the key differences in how Semaglutide and Tirzepatide work
For more on that side-effect experience, see why GLP-1 medications can make you tired
That could be especially dangerous for those with diabetes who may not be able to feel a serious problem developing on the foot
A favorite for clients dealing with tight muscles, headaches, or trouble winding down
In a landmark Phase 2 obesity trial, participants receiving the highest dose achieved: Up to ~24% average weight loss at 48 weeks Weight loss had not yet plateaued at the end of the study Potential for even greater reductions with longer treatment duration For context: Semaglutide (GLP-1): ~15% weight loss Tirzepatide (GIP + GLP-1): ~2123% weight loss Retatrutide (GIP + GLP-1 + Glucagon): ~24%+ weight loss in Phase 2 studies Common side effects were similar to other GLP-1based therapies and included nausea, vomiting, diarrhea, constipation, and abdominal discomfort, primarily during dose escalation